I'm LongbridgeAI, I can summarize articles.Armata Pharmaceuticals reported a Q2 net income of $74.14 million, reversing last year's loss, driven by an $84.45 million non-cash gain from convertible loan fair-value changes. However, the operating loss widened to $10.31 million due to higher R&D and G&A expenses. Grant revenue rose 15.7% to $2.51 million. The company plans to initiate a pivotal Phase 3 study for AP-SA02 in complicated S. aureus bacteremia in H2 2026, following FDA Fast Track designation.
- Armata Pharmaceuticals posted Q2 net income of USD 74.14 million, swinging from a net loss a year earlier. * Operating loss widened to USD 10.31 million from USD 6.84 million, on higher R&D and G&A expenses. * Grant and award revenue rose 15.72% to USD 2.51 million. * Other income totaled USD 84.45 million, driven by a USD 91.02 million non-cash gain from the Convertible Loan fair-value change. * Company expects to initiate a pivotal Phase 3 superiority study of AP-SA02 in complicated S. aureus bacteremia in 2H 2026; FDA granted Fast Track. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608121605PR_NEWS_USPR_____LA23099) on August 12, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)